SI2868315T1 - Izboljšane formulacije in metode za liofilizacijo in liofilizate zagotovljene z le-to - Google Patents

Izboljšane formulacije in metode za liofilizacijo in liofilizate zagotovljene z le-to

Info

Publication number
SI2868315T1
SI2868315T1 SI200831850T SI200831850T SI2868315T1 SI 2868315 T1 SI2868315 T1 SI 2868315T1 SI 200831850 T SI200831850 T SI 200831850T SI 200831850 T SI200831850 T SI 200831850T SI 2868315 T1 SI2868315 T1 SI 2868315T1
Authority
SI
Slovenia
Prior art keywords
lyophilates
lyophilization
methods
improved formulations
formulations
Prior art date
Application number
SI200831850T
Other languages
English (en)
Inventor
Martin Sven Jacobson
Original Assignee
Biogen Chesapeake Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake Llc filed Critical Biogen Chesapeake Llc
Publication of SI2868315T1 publication Critical patent/SI2868315T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
SI200831850T 2007-12-04 2008-12-03 Izboljšane formulacije in metode za liofilizacijo in liofilizate zagotovljene z le-to SI2868315T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99224107P 2007-12-04 2007-12-04
EP14188334.8A EP2868315B1 (en) 2007-12-04 2008-12-03 Improved formulations and methods for lyophilization and lyophilates provided thereby

Publications (1)

Publication Number Publication Date
SI2868315T1 true SI2868315T1 (sl) 2017-10-30

Family

ID=40718143

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831850T SI2868315T1 (sl) 2007-12-04 2008-12-03 Izboljšane formulacije in metode za liofilizacijo in liofilizate zagotovljene z le-to

Country Status (14)

Country Link
US (6) US8277845B2 (sl)
EP (2) EP2224913B1 (sl)
JP (5) JP5812318B2 (sl)
CN (1) CN101932308B (sl)
CA (2) CA3123813A1 (sl)
CY (1) CY1119256T1 (sl)
DK (1) DK2868315T3 (sl)
ES (1) ES2638977T3 (sl)
HR (1) HRP20171223T1 (sl)
LT (1) LT2868315T (sl)
PL (1) PL2868315T3 (sl)
PT (1) PT2868315T (sl)
SI (1) SI2868315T1 (sl)
WO (1) WO2009073711A1 (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2224913B1 (en) * 2007-12-04 2014-10-15 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
US20110034560A1 (en) 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
US20140287998A1 (en) * 2011-12-09 2014-09-25 Enject, Inc. Glucagon formulations
ES2699646T3 (es) 2012-05-08 2019-02-12 Aeromics Inc Compuestos para uso en el tratamiento de enfermedades mediadas por acuaporina
LT2800811T (lt) * 2012-05-25 2017-09-11 The Regents Of The University Of California Būdai ir kompozicijos, skirti tikslinės dnr modifikavimui, panaudojant adresuotą rnr, ir transkripcijos moduliavimui, panaudojant adresuotą rnr
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
US9827253B2 (en) 2013-11-06 2017-11-28 Aeromics, Inc. Prodrug salts
CN106456315B (zh) * 2014-03-07 2021-06-25 恩朵罗杰克斯有限责任公司 形成水凝胶和用于形成水凝胶的材料
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
CA2988417C (en) 2015-05-29 2022-10-11 Biogen Chesapeake, Llc Methods of reducing or preventing intimal damage caused by mechanical stimulation of endothelial cells
KR20180063296A (ko) 2015-10-07 2018-06-11 바이오젠 체사피크 엘엘씨 Cns 부종과 관련한 손상 또는 병태의 치료 방법
US20170320862A1 (en) 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
EP3490545B1 (en) 2016-07-29 2023-11-15 Remedy Pharmaceuticals, Inc. Methods of medical treatment with sur1-trpm4 channel inhibitors
CN108210501B (zh) * 2016-12-14 2019-03-08 中国人民解放军军事医学科学院毒物药物研究所 一种磺酰脲类药物的注射用药物组合物及其制备方法
KR102336425B1 (ko) 2017-06-30 2021-12-07 무라다기카이가부시끼가이샤 반송 시스템 및 반송 방법
CN108553428A (zh) * 2018-05-29 2018-09-21 昆药集团股份有限公司 格列本脲制剂及其制备方法
WO2022195112A1 (en) 2021-03-19 2022-09-22 Eligo Bioscience Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins for treating acneiform rash
CN113274361B (zh) * 2021-06-08 2022-05-06 吉林津升制药有限公司 一种烟酰胺冻干粉针剂及其制备方法
WO2023168379A1 (en) * 2022-03-03 2023-09-07 Biogen Chesapeake Llc Low-sorbing glyburide kit, formulation and methods

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
GB9003185D0 (en) * 1990-02-13 1990-04-11 Ici Plc Pharmaceutical compositions
EP0621774B1 (en) 1992-01-21 1996-12-18 Sri International Improved process for preparing micronized polypeptide drugs
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
CN1046516C (zh) * 1994-04-25 1999-11-17 协和发酵工业株式会社 化合物dx－52－1的稳定方法和其冻干组合物
US5747002A (en) 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US5856360A (en) * 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
US5817343A (en) 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
CN1222315C (zh) * 1996-12-24 2005-10-12 拜奥根有限公司 稳定的液体干扰素制剂
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
ES2219895T3 (es) 1997-07-29 2004-12-01 PHARMACIA &amp; UPJOHN COMPANY Formulacion autoemulsionante para compuestos lipofilos.
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
EP1082132A1 (en) * 1998-05-29 2001-03-14 Biogen, Inc. Recombinant human interferon beta-1a (ifn-beta-1a) formulation
US6552082B2 (en) 2000-06-29 2003-04-22 Ono Pharmaceutical Co., Ltd. Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof
JP3956654B2 (ja) 2000-06-29 2007-08-08 小野薬品工業株式会社 Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤
US20030175349A1 (en) 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
WO2002079778A2 (en) 2001-03-28 2002-10-10 Rheologics, Inc. In vivo delivery methods and compositions
US20080220441A1 (en) * 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
WO2002100836A2 (en) * 2001-06-12 2002-12-19 Active Pass Pharmaceuticals, Inc. Compounds, compositions and methods for modulating beta-amyloid production
RU2311907C2 (ru) * 2001-07-17 2007-12-10 Н-Джин Ресерч Лабораториз Инк. Синергичный фармацевтический состав для профилактики или лечения диабета
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
WO2003079987A2 (en) * 2002-03-20 2003-10-02 University Of Maryland Baltimore A non-selective cation channel in neural cells and methods for treating brain swelling
DE10325989A1 (de) 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
GB0316237D0 (en) * 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
DE10341414A1 (de) * 2003-09-05 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe
CA2566873C (en) * 2004-05-20 2013-02-12 Diamedica Inc. Use of drug combinations for treating insulin resistance
EP1799227B1 (en) * 2004-09-18 2010-11-10 University of Maryland, Baltimore Therapeutic agents targeting the nc ca-atp channel and methods of use thereof
US20060183803A1 (en) * 2005-02-17 2006-08-17 Instituto Del Metabolismo Celular, S.L. L-aspartic acid for the treatment of assorted health problems
US7659281B2 (en) * 2006-04-25 2010-02-09 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors
KR101412296B1 (ko) 2006-09-29 2014-06-25 인파 에스. 에이. 약제학적 조성물용 포장 시스템과 정맥 투여용 키트
EP2224913B1 (en) * 2007-12-04 2014-10-15 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby

Also Published As

Publication number Publication date
US20210244669A1 (en) 2021-08-12
JP2011505424A (ja) 2011-02-24
CA2707484C (en) 2021-08-10
EP2224913A4 (en) 2013-04-24
US20130245069A1 (en) 2013-09-19
EP2868315B1 (en) 2017-05-31
JP2020007334A (ja) 2020-01-16
US10117834B2 (en) 2018-11-06
JP2017128569A (ja) 2017-07-27
PT2868315T (pt) 2017-09-04
US10869835B2 (en) 2020-12-22
US8858997B2 (en) 2014-10-14
CA2707484A1 (en) 2009-06-11
ES2638977T3 (es) 2017-10-24
JP6603762B2 (ja) 2019-11-06
US20100273886A1 (en) 2010-10-28
US10426729B2 (en) 2019-10-01
US8277845B2 (en) 2012-10-02
JP6866438B2 (ja) 2021-04-28
JP2018197244A (ja) 2018-12-13
EP2224913A1 (en) 2010-09-08
HRP20171223T1 (hr) 2017-11-03
CY1119256T1 (el) 2018-02-14
CA3123813A1 (en) 2009-06-11
EP2224913B1 (en) 2014-10-15
JP5812318B2 (ja) 2015-11-11
JP6084639B2 (ja) 2017-02-22
DK2868315T3 (en) 2017-09-04
PL2868315T3 (pl) 2018-06-29
LT2868315T (lt) 2017-09-25
WO2009073711A1 (en) 2009-06-11
US20200093747A1 (en) 2020-03-26
JP2015134763A (ja) 2015-07-27
CN101932308A (zh) 2010-12-29
EP2868315A1 (en) 2015-05-06
CN101932308B (zh) 2014-11-05
US20190099372A1 (en) 2019-04-04
JP6377189B2 (ja) 2018-08-22
US20150141516A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
HRP20171223T1 (hr) Poboljšane formulacije i postupci liofiliziranja i tako dobiveni liofilizati
HK1218427A1 (zh) 改進的疫苗及其使用方法
EP2043647A4 (en) FORMULATION WITH TAXED RELEASE AND CORRESPONDING METHODS
ZA201203709B (en) Immunogenic compositions and methods
HK1138188A1 (en) Solid preparation comprising alogliptin and pioglitazone
IL194653A0 (en) Lyophilized therapeutic peptibody formulations
IL197781A0 (en) Lyophilization methods and apparatuses
EP2461691A4 (en) THERAPEUTIC VITAMIN D SUNSCREEN FORMULATIONS AND METHOD OF USE THEREOF
HK1244426A1 (zh) 治療性蛋白質製劑
EP2367444A4 (en) MEDICAL AND NUTRITIONAL FORMULATIONS
EP2209750A4 (en) CEMENT FORMULATIONS AND PRODUCTS
EP2185112A4 (en) STABILIZED THERAPEUTIC COMPOSITIONS AND FORMULATIONS
EP2160183A4 (en) QUETIPIN EXTENDED FORMULATIONS WITH EXTENDED RELEASE AND METHOD OF MANUFACTURING THEREOF
GB0719202D0 (en) Compositions and methods for the skin and hair
PL2207567T3 (pl) Preparat immunogenny
EP2320739A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR STABILIZATION
ZA200903049B (en) Polymer-linked-bisphosphonate inhalant formulations and methods for using the same
ZA201003524B (en) Injectable meclizine formulations and methods
ZA201008384B (en) Lasalocid compositions and methods
EP2348865A4 (en) BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES, THEIR METHODS OF PREPARATION AND THEIR USE
GB0711465D0 (en) Silan-3-amines and disilan-5-amines as therapeutic agents
GB0725007D0 (en) Carcino-immune therapeutic animal gland extract
GB0713093D0 (en) Pharmaceutical formulations
GB0715066D0 (en) Tobacco extraction methods and formulations